Free Trial
NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Price, News & Analysis

Pacira BioSciences logo
$19.20 +0.22 (+1.16%)
(As of 05:45 PM ET)

About Pacira BioSciences Stock (NASDAQ:PCRX)

Key Stats

Today's Range
$18.96
$19.66
50-Day Range
$16.37
$20.33
52-Week Range
$11.16
$35.95
Volume
897,189 shs
Average Volume
859,281 shs
Market Capitalization
$886.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50
Consensus Rating
Hold

Company Overview

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Pacira BioSciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
76th Percentile Overall Score

PCRX MarketRank™: 

Pacira BioSciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 253rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 4 buy ratings, 4 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Pacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pacira BioSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Pacira BioSciences are expected to decrease by -11.21% in the coming year, from $2.32 to $2.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pacira BioSciences is -9.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pacira BioSciences is -9.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pacira BioSciences has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.40% of the outstanding shares of Pacira BioSciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Pacira BioSciences has recently decreased by 0.41%, indicating that investor sentiment is improving.
  • Dividend Yield

    Pacira BioSciences does not currently pay a dividend.

  • Dividend Growth

    Pacira BioSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.40% of the outstanding shares of Pacira BioSciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Pacira BioSciences has recently decreased by 0.41%, indicating that investor sentiment is improving.
  • News Sentiment

    Pacira BioSciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Pacira BioSciences this week, compared to 5 articles on an average week.
  • Search Interest

    1 people have searched for PCRX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,880.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Pacira BioSciences is held by insiders.

  • Percentage Held by Institutions

    99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pacira BioSciences' insider trading history.
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Stock News Headlines

Equities Analysts Offer Predictions for PCRX FY2024 Earnings
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Q1 EPS Forecast for Pacira BioSciences Lowered by Analyst
DOMA Perpetual Capital to nominate four candidates to Pacira’s board
See More Headlines

PCRX Stock Analysis - Frequently Asked Questions

Pacira BioSciences' stock was trading at $33.74 at the beginning of the year. Since then, PCRX shares have decreased by 43.1% and is now trading at $19.20.
View the best growth stocks for 2024 here
.

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported $0.72 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.07. The company's quarterly revenue was up 8.7% on a year-over-year basis.

Top institutional shareholders of Pacira BioSciences include Pacer Advisors Inc. (10.75%), State Street Corp (4.36%), Geode Capital Management LLC (2.35%) and Assenagon Asset Management S.A. (1.20%). Insiders that own company stock include David M Stack, Daryl Gaugler, Kristen Williams, Jonathan Slonin, Roy Winston, Lauren Riker, Charles A Reinhart III, Max Reinhardt, Charles Anthony Laranjeira, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson, Marcelo Bigal and John P Phd Longenecker.
View institutional ownership trends
.

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
11/02/2021
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
720
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.50
High Stock Price Target
$57.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+22.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$41.96 million
Pretax Margin
-7.91%

Debt

Sales & Book Value

Annual Sales
$694.96 million
Cash Flow
$3.82 per share
Book Value
$18.74 per share

Miscellaneous

Free Float
43,218,000
Market Cap
$886.52 million
Optionable
Optionable
Beta
0.80

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:PCRX) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners